Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Chacra AR, et al. Int J Clin Pract. 2009 Sep;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.x. Epub 2009 Jul 15. Int J Clin Pract. 2009. PMID: 19614786 Free PMC article. Clinical Trial.
Managing diabetes in Asia: overcoming obstacles and the role of DPP-IV inhibitors.
Mu YM, Misra A, Adam JM, Chan SP, Chow FC, Cunanan EC, Deerochanawong C, Jang HC, Khue NT, Sheu WH, Tan KE. Mu YM, et al. Among authors: jang hc. Diabetes Res Clin Pract. 2012 Feb;95(2):179-88. doi: 10.1016/j.diabres.2011.09.023. Epub 2011 Oct 22. Diabetes Res Clin Pract. 2012. PMID: 22019271 Review.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW; Gemigliptin Study 006 Group. Rhee EJ, et al. Among authors: jang hc. Diabetes Obes Metab. 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. Epub 2013 Jan 30. Diabetes Obes Metab. 2013. PMID: 23320436 Clinical Trial.
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Hwang YC, et al. Among authors: jang hc. Int J Clin Pract. 2013 Mar;67(3):236-43. doi: 10.1111/ijcp.12071. Epub 2013 Jan 22. Int J Clin Pract. 2013. PMID: 23336668 Clinical Trial.
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, Choi SH, Jang HC, Lim S. Hong AR, et al. Among authors: jang hc. Diabetes Res Clin Pract. 2015 Jul;109(1):141-8. doi: 10.1016/j.diabres.2015.04.019. Epub 2015 May 5. Diabetes Res Clin Pract. 2015. PMID: 26003889 Clinical Trial.
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, Lee HW, Lee DH, Kim J, Chung CH, Park TS, Kim BJ, Park SW, Park HK, Lee KJ, Kim SW, Park JH, Ko KP, Kim CH, Lee H, Jang HC, Park KS. Ahn CH, et al. Among authors: jang hc. Diabetes Obes Metab. 2017 May;19(5):635-643. doi: 10.1111/dom.12866. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 28026912 Clinical Trial.
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Jung CH, Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS; Gemigliptin Study 006 Group. Jung CH, et al. Among authors: jang hc. Diabetes Obes Metab. 2018 Jun;20(6):1535-1541. doi: 10.1111/dom.13256. Epub 2018 Apr 6. Diabetes Obes Metab. 2018. PMID: 29436761 Clinical Trial.
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y, Kang ES, Jang HC, Kim DJ, Oh T, Kim ES, Kim NH, Choi KM, Kim SR, You J, Kim SJ, Lee MK. Kim Y, et al. Among authors: jang hc. Diabetes Obes Metab. 2019 Mar;21(3):631-639. doi: 10.1111/dom.13566. Epub 2018 Nov 22. Diabetes Obes Metab. 2019. PMID: 30362280 Free PMC article. Clinical Trial.
497 results